Of Mice and Me Chapter 2 Review Questions

• Periodical List
• HHS Writer Manuscripts
• PMC2832725

J Allergy Clin Immunol. Author manuscript; bachelor in PMC 2011 Feb 1.

Published in concluding edited grade as:

PMCID: PMC2832725

NIHMSID: NIHMS161342

Chapter 2: Innate Amnesty

Stuart E. Turvey

¹Department of Paediatrics, BC Children's Hospital and Child & Family Research Institute, University of British Columbia, Vancouver, BC, Canada.

David H. Broide

²Department of Medicine, University of California San Diego, La Jolla, CA, Us.

Abstract

Contempo years take witnessed an explosion of interest in the innate allowed organisation. Questions about how the innate immune system senses infection and empowers a protective immune response are existence answered at the molecular level. These basic scientific discipline discoveries are existence translated into a more than complete understanding of the key part innate immunity plays in the pathogenesis of many human infectious and inflammatory diseases. It is particularly exciting that nosotros are already seeing a return on these scientific investments with the emergence of novel therapies to harness the power of the innate immune system. In this review nosotros explore the defining characteristics of the innate immune arrangement, and through more detailed examples, we highlight recent breakthroughs that have advanced our understanding of the function of innate immunity in human health and disease.

Keywords: host defense, innate amnesty, Toll-like receptors, NOD-like receptors

THE "NEW" SCIENCE OF INNATE Amnesty

The integrated human allowed response has traditionally been divided into ii branches: innate and adaptive (or acquired) immunity. While appreciation of innate immunity dates back to at to the lowest degree the 1908 Nobel Prize winning efforts of Ilya Mechnikov; until the last decade, study of innate immunity has been eclipsed by dramatic discoveries in the field of adaptive immunity. Withal, the contempo molecular definition of how the innate allowed organization senses infection to empower protective immune responses has precipitated a renaissance in the field of innate immunity. Innate immunity has shed its older, disparaging championship of 'non-specific immunity' and at present stands as a proud partner with the adaptive immune system in protecting homo hosts from infectious insults. For any who dubiousness the impressive protective capacity of the innate allowed system, it is instructive to consider that only vertebrates boast the added benefits of an adaptive immune system, leaving about organisms on our planet to survive on innate immunity lonely!

While innate immunity is disquisitional for host defence force against infectious challenges, the innate immune system is emerging equally a critical regulator of man inflammatory affliction. Indeed, innate immune responses have been implicated in the development of asthma and atopy, as well as a variety of autoimmune disorders including Type 1 diabetes, inflammatory bowel illness and systemic lupus erythematosus.

In this review nosotros examine the bones structure of the innate immune system and how innate immunity interfaces with adaptive immune responses. Nosotros explore the role of innate immunity in human being wellness and disease and nosotros outline how novel therapies may harness the beneficial capacity of the innate allowed organisation. Rather than attempting to comprehensively review this enormously broad topic, our focus is on highlighting common defining mechanisms of innate immunity and illustrating the clinical relevance of innate immunity to human health. We accept deliberately avoided a detailed exploration of the complement system as a separate Primer affiliate is devoted to this of import attribute of innate amnesty (Chapter 23: Complement Disorders and Hereditary Angioedema. Michael Frank).

ORGANIZATION OF THE Human being Immune SYSTEM: 3 LEVELS OF HOST DEFENSE

The man microbial defense system can be simplistically viewed every bit consisting of iii levels: (i) anatomical and physiological barriers; (ii) innate amnesty; and (iii) adaptive amnesty (Figure ane and Table 1). Failure in any of these systems will greatly increase susceptibility to infection.

Integrated Man Allowed System

The man microbial defense system can be simplistically viewed as consisting of three levels: (i) anatomical and physiological barriers; (2) innate amnesty; and (iii) adaptive immunity. In common with many nomenclature systems, some elements are difficult to categorize. For instance, NKT cells and DCs could be classified as being on the cusp of innate and adaptive immunity rather than existence firmly in one army camp.

Tabular array 1

Overview of Defining Features of Innate and Adaptive Immunity

Comparing and contrasting some of the defining features of the innate and adaptive allowed systems. Adapted from [one].

	Innate Immune System	Adaptive Immune Arrangement
Cellular elements	Hematopoietic cells: macrophages, dendritic cells, mast cells, neutrophils, eosinophils, natural killer cells & natural killer T cells.	Hematopoietic cells: T & B lymphocytes.
	Non-hematopoietic cells: epithelial cells (e.g. peel, airways, gastrointestinal tract).
Humoral elements	Large arsenal of components: Complement proteins, LPS bounden poly peptide, C-reactive protein and other acute stage reactants, anti-microbial peptides, mannose-binding lectin.	Immunoglobulins secreted by B cells.
Receptor characteristics	Invariant, germline encoded.	Generated by random somatic gene-segment rearrangement.
	All cells of a course express identical receptors (i.due east. non-clonal).	All cells of a class express a single blazon of receptor with unique specificity (i.e. clonal).
Ligands recognized	Conserved microbial components.	Specific 'details' or epitopes of macromolecules (e.g. proteins, peptides, carbohydrates).
	Mutual metabolic or biological consequences of infection (e.thou. uric acid, K+ efflux, MHC class I downregulaton).
Types of receptors	Activating: TLR, NLR, complement.	B cell receptor and T jail cell receptor.
	Inhibitory: Killer cell immunoglobulin-similar receptors (KIR).
Response time	Immediate	Delayed by hours to days.
Immunological retentivity	None. Responses are the same with each exposure. Non-anticipatory immunity	Responsiveness enhanced past repeated antigen exposure. Anticipatory immunity.
Adventure of autoreactivity	Low. Self-tolerant receptors selected during evolution	High. Random cistron rearrangement generates autoreactive receptors requiring presence of multiple tolerance mechanisms.

Anatomical and physiological barriers provide the crucial beginning line of defence against pathogens. These barriers include intact skin, vigorous mucociliary clearance mechanisms, low breadbasket pH and bacteriolytic lysozyme in tears, saliva and other secretions. The extreme susceptibility to infections observed in individuals with severe cutaneous burns or primary ciliary dyskinesia demonstrates that intact innate and adaptive immune systems are not able to compensate for failure of essential anatomical and physiological barriers.

Innate immunity augments the protection offered past anatomical and physiological barriers.¹ The innate allowed organisation relies upon a limited repertoire of receptors to detect invading pathogens, only compensates for this limited number of invariant receptors by targeting conserved microbial components that are shared past large groups of pathogens. Speed is a defining feature of the innate immune organization—within minutes of pathogen exposure the innate immune system starts generating a protective inflammatory response. Moreover, innate immunity plays a fundamental role in activating the subsequent adaptive immune response.

T- and B-lymphocytes are the main self-defense weapons of the adaptive immune system, so-named considering this system is shaped by antigen exposure. In contrast to the express number of pathogen receptors utilized by the innate allowed system, the adaptive allowed system boasts an extremely diverse, randomly-generated repertoire of receptors. The benefit of this receptor multifariousness is that the adaptive immune arrangement tin recognize about any antigen, simply there is a cost for this multifariousness. Commencement is the hazard of autoimmune disease. Receptors specific for self proteins (such every bit insulin and myelin) are created past the random process of gene rearrangement that generates receptors expressed by T cells and B cells. Consequently, elaborate tolerance mechanisms accept evolved to eliminate or regulate self-reactive cells. Second is the time delay required to generate a protective adaptive immune response following the first exposure to a pathogen. Adaptive immunity relies upon a clonal arrangement with each T jail cell and B cell expressing its own unique receptor and following the initial encounter with a pathogen, it takes up to five days for clonal expansion of these rare antigen-specific T and B cells to occur before the adaptive immune response is sufficiently robust to articulate the pathogen.

ELEMENTS OF THE INNATE Immune Organisation

In contrast to the adaptive immune system which depends upon T and B lymphocytes, innate immune protection is a task performed by cells of both hematopoietic and not-hematopoietic origin (Figure 1 and Table i). Hematopoietic cells involved in innate immune responses include macrophages, dendritic cells, mast cell, neutrophils, eosinophils, natural killer (NK) cells and natural killer T cells. In addition to hematopoietic cells, innate immune responsiveness is a holding of the peel and the epithelial cells lining the respiratory, gastrointestinal and genitourinary tracts.

To augment these cellular defenses, innate immunity also has a humoral component that includes well characterized components such as complement proteins, LPS bounden protein (LBP), C-reactive protein and other pentraxins, collectins, and anti-microbial peptides including defensins. Circulating innate immune proteins are involved in both in sensing microbes and effector mechanisms to facilitate clearance of the infection. For example, mannose-binding lectin (MBL), a member of the collectin family of receptors, binds mannose-containing carbohydrates on microbes triggering activation of the complement cascade which enhances clearance of the pathogen.

HOST DEFENSE IS Accomplished THROUGH INTEGRATION OF INNATE AND ADAPTIVE IMMUNITY

Innate immunity, an evolutionarily ancient component of host defense, is present in all multicellular organisms while adaptive immunity evolved much after and is only institute in jawed fish and all 'college' vertebrates.² During evolution, adaptive immunity developed in the context of a operation innate immune system. Consequently, the classic demarcation between innate and adaptive amnesty is overly simplistic as many adaptive allowed responses build on the foundation of innate amnesty. For example, the capacity of neutrophils to impale bacteria is enhanced when the leaner are opsonized by antibodies produced through the coordinated efforts of T and B cells. In a like fashion, the C3d fragment that is generated in the course of complement activation acts every bit a molecular adjuvant to profoundly influence the subsequent adaptive allowed response. Specifically, Cd3 fragments act to bridge innate and adaptive amnesty as covalent binding of single or multiple copies of C3d to a strange antigen generally enhances B prison cell effector and memory part.ⁱⁱⁱ Some other illustrative instance of the interdependence of innate and adaptive amnesty is the disquisitional role played by antigen-presenting cells of the innate immune system (east.g. dendritic cells) to empower total activation of the T and B cells of the adaptive immune arrangement. Further blurring of the distinction between innate and adaptive amnesty is highlighted by the fact that cells of the adaptive immune system, including regulatory T lymphocytes, express Toll-like receptors (TLRs) and other innate immune receptors.^iv The inter-relatedness of innate and adaptive immunity is most eloquently articulated past Beutler in his observation that "…the roots of adaptive immunity are buried deep in the soil of the innate immune system".⁵

INNATE IMMUNE RECOGNITION STRATEGIES

The innate immune arrangement serves as the initial immune defence force against foreign and dangerous material. In the about simplistic view, the innate immune system is hardwired with germline-encoded receptors for immediate responsiveness. In dissimilarity to adaptive immunity, innate immune responses do not require genetic recombination events or a developmental stage to mediate office.

The strategy used for immune recognition is the main feature distinguishing innate and adaptive amnesty. In dissimilarity to the massive, randomly-generated repertoire of antigen receptors expressed by T and B lymphocytes, the innate allowed organisation relies upon a limited number of genetically predetermined germline-encoded receptors that recognize either highly conserved structures expressed by large groups of microbes or common biological consequences of infection. Pathogens tin can rapidly evolve and, in principle, could avoid detection past the innate allowed system past simply altering the targeted microbial molecules. However, the innate immune system has evolved to recognize either microbial components that are essential for the viability and virulence of microbes and are thus less prone to modifications, or common biological consequences of infection.

At least three broad strategies are used past the innate immune organization to recognize invading microorganisms (Table 2). In the first, innate immunity relies upon a limited repertoire of germline-encoded receptors to recognize 'microbial non-cocky' – conserved molecular structures that are expressed by a large variety of microbes. Charles Janeway coined the terms 'pattern recognition receptors' (PRRs) to collectively describe these receptors and 'pathogen-associated molecular patterns' (PAMPs) to denote the microbial structures recognized past the PRRs.⁶ However, this terminology has been criticized as being vague⁵; therefore in this review nosotros will focus on naming specific receptors and their microbial ligands. A 2nd approach used past the innate immune system is to notice immunological 'danger' in the grade of 'damage-associated molecular patterns' (DAMPs). DAMPs represents common metabolic consequences of infection and inflammation.⁷ DAMPs are molecules that are upregulated and released during the prison cell lysis and tissue impairment that occurs in the context of both infectious and sterile inflammation. Well characterized DAMPs include high mobility grouping box 1 protein (HMGB-i) and other endogenous alarmins, estrus-shock proteins (HSPs) and uric acid. In the third innate immune recognition strategy, innate immune receptors detect "missing self" – molecules expressed by normal, healthy cells but not expressed by infected cells or microbes. Recognition of these signals indicates that 'all-is-well' and an inhibitory betoken is delivered to prevent activation of the immune response confronting host tissues. This inhibitory system is well illustrated by NK cells. Inhibitory receptors specific for cocky-MHC course I molecules play a central role in missing-self recognition by NK cells, ensuring NK cells preferentially attack infected cells that downregulate their MHC class I proteins.^viii

Table two

Common Innate Immune Recognition Strategies

Innate Immune Recognition Strategy	Receptor Families	Specific examples
		Receptor	Ligand
ane. Detecting 'microbial non-cocky'     (i.e. pathogen-associated     molecular patterns (PAMPs))	Price-like receptors	TLR4	Lipopolysaccharide
		TLR5	Flagellin (extracellular)
	NOD-like receptors	NOD2	Muramyl dipeptide
		IPAF	Flagellin (intracellular)
	Collectin family	MBP	Microbial terminal mannose residues
ii. Detecting common metabolic     consequences of jail cell infection     or injury     (i.e. damage-associated     molecular patterns (DAMPs))	NOD-like receptors	NLRP3 (or NALP3)	Uric acid, G+ efflux, ATP
	RAGE (receptor of advance glycation end production) family	RAGE	HMGB1, S100
3. Detecting 'missing self'	MHC-form-I-specific inhibitory receptors	KIR	Self MHC class I (inhibitory signal)
		CD94-NKG2A heterodimers	Self MHC class I (inhibitory signal)

ROLE OF THE INNATE Immune Organization IN Health AND DISEASE

Nosotros will now turn our attention to specific components of the innate immune organization. We deliberately selected 2 illustrative examples – TLRs and NLRs – where our mechanistic agreement has increased considerably in the past 5 years and where the clinical relevance of these systems is commencement to emerge.

1. Price-Similar RECEPTORS (TLRS)

Overview of TLR Structure and Function

The recent explosion of interest in innate immunity was catalyzed in the mid-1990s when the Drosophila poly peptide Toll was shown to be critical for defending fruit flies against fungal infections.^nine This observation opened the way for the subsequent description of similar proteins, called Price-similar receptors (TLRs), in mammalian cells. The human TLR family consists of 10 receptors that are critically important for innate immunity.^{x , 11} TLRs permit for recognition and response to diverse microbial epitopes on pathogens enabling the innate immune organisation to discriminate amidst groups of pathogens and to induce an appropriate pour of effector adaptive responses.

TLRs exist every bit dimeric proteins (either heterodimers or homodimers). The ectodomains of TLRs are equanimous of leucine-rich repeat motifs while the cytosolic component, called a Cost/interleukin-i receptor (TIR) domain, is involved in signaling. Individual TLRs recognize a singled-out, only limited, repertoire of conserved microbial products; for example, well characterized receptor-ligand pairs include TLR4 and lipopolysaccharide (LPS), TLR5 and flagellin, TLRs1/2/half-dozen and lipoproteins. Collectively, the consummate TLR family unit allows the host to find infection by nearly (if non all) types of microbial pathogens. For case, Gram positive organisms, such every bit Streptococcus pneumoniae, are initially recognized past TLR1, 2, 4, six and ix, which in plough interact with a range of downstream signaling molecules to activate an inflammatory cascade. TLR signaling pathways take been the focus of considerable attention (reviewed in ^{11 , 12} and depicted in Effigy 2). The emerging model has ligation of microbial products by TLRs culminating in the activation of nuclear factor kappa-B (NF-κB), activator protein-one (AP-one), interferon-regulatory factor (IRF)-three and other transcription factors, driving the product of proinflammatory cytokines, maturation of dendritic cells and other immunological responses.

Overview of TLR Signaling and the NLRP3 Inflammasome

TLR ligation initiates a signaling cascade that culminates in the translocation of the transcription factors, NF-κB and others, to the nucleus generating an acute inflammatory response. The NLRP3 (or NALP3) inflammasome is triggered by a wide diversity of stimuli culminating in the activation of caspase i which will and then cleave pro-IL1β and pro-IL18 to drive an inflammatory response. Man mutations and polymorphisms in many of the genes encoding elements of these pathways announced to alter susceptibility to infectious and inflammatory diseases.

Homo Disease Resulting from TLR Defects

Naturally-occurring genetic mutations in humans, causing extreme immunodeficiency phenotypes, present powerful opportunities to make up one's mind the relationship between specific immunological defects and human disease processes in vivo. Contempo clarification of homo primary immunodeficiencies associated with abnormal TLR signaling demonstrate that this pathway is critical for homo defense force confronting infection. Empowered by technological advances in genotyping and bioinformatics, we are now beginning to appreciate how common genetic variation and polymorphisms in genes controlling the innate immune response alters infectious susceptibility in a subtle simply specific style. Importantly, human primary immunodeficiencies associated with abnormal TLR signaling provide unique insights into the immunological pathways vital for host defense and identify candidate genes that may cause subtle immunodeficiencies in the broader population of evidently good for you people^thirteen.

a) Monogenic primary immunodeficiencies

Interleukin-1 receptor associated kinase 4 (IRAK4) deficiency (OMIM #607676)¹⁴ and myeloid differentiation primary response gene 88 (MyD88) deficiency (OMIM #612260)^fifteen are novel primary immunodeficiencies specifically affecting TLR function. MyD88 and IRAK4 are binding partners involved in downstream signaling from most TLRs (Figure 2); hence, the clinical and laboratory phenotypes of IRAK4- and MyD88-deficiencies are identical. The narrow spectrum of infections experienced past afflicted individuals is hit in light of their profound impairment of TLR function and pathogen sensing. IRAK4- and MyD88-deficient patients predominantly suffer from recurrent infections caused by pyogenic Gram-positive bacteria, with Streptococcus pneumoniae causing invasive infection in all reported cases while Staphylococcus aureus and Pseudomonas aeruginosa caused infections in well-nigh half the patients. The surprising clinical observation that IRAK4-deficient patients are resistant to viral infections was recently explained at a molecular level as IRAK4-deficient patients are able to control viral infections past TLR3- and TLR4-dependent product of IFNs.^xvi

Arguably one of the most powerful letters to ascend from the recognition of IRAK4- and MyD88-deficiency is the value of studying humans to understand human immune function! While MyD88-deficient patients are susceptible to Streptococcus pneumoniae and a limited number of pyogenic leaner, they are able to resist infection past nearly common bacteria, viruses, fungi, and parasites. In dissimilarity, MyD88-deficiency renders mice profoundly susceptible to near pathogens tested.

b) Contribution of TLR polymorphisms to human affliction

At the population level susceptibility to common diseases, such as infections, seldom follows the simple blueprint of Mendelian inheritance seen in IRAK4- and MyD88-deficiency.¹⁷ About infections follow a complex fashion of inheritance, with disease arising from an intricate interplay betwixt environmental and genetic factors. The complexity of common infectious diseases has fabricated them, until very recently, largely impervious to genetic analysis. Still, advances in high throughput genotyping techniques and bioinformatics is now allowing us to understand how mutual genetic variants alter human susceptibility to infection.

Although humans are identical at well-nigh of the 3 billion base pairs in their genome, inter-private variation is present in approximately 3 million nucleotides (i.e. 0.1% of the genome).^eighteen A common type of human genetic variation is the single nucleotide polymorphism (SNP), where 2 culling bases occur at observable frequency (>1%) in the population. There is convincing prove that common TLR SNPs regulate cellular signaling events, cytokine product and susceptibility to infection based on the specific pathogens recognized past the TLR. Arguably the best evidence implicates amino acrid changing (i.e. not-synonymous) SNPs in TLRs 1, 2 and 5, as well equally variants in the adaptor molecule TIR domain-containing adaptor protein (TIRAP, also know every bit MAL). This genetic variation in the population results in some individuals having a 'subtle' simply specific immunodeficiency. For case, a common TLR5 polymorphism in the ligand-binding domain of TLR5 (392STOP) abolishes flagellin signaling and is associated with increased susceptibility to Legionnaire's disease caused past the flagellated bacterium, Legionella pneumophila.^xix In a similar fashion, polymorphisms in the adaptor molecule MAL/TIRAP which mediates signaling through TLR1, two, 4, and vi, have been associated with susceptibility to tuberculosis, malaria and pneumococcal affliction.^xx

Given the role of TLRs in sensing the extracellular environs and shaping inflammatory response, the TLR pathway has been hypothesized to influence the development of atopy and asthma. The all-time studied case is CD14. CD14 is encoded on chromosome 5q31.1 in a region linked to atopy and asthma, and CD14 partners with TLR4 to recognize LPS. Therefore, a SNP in this factor (CD14/–159 C to T) which appeared to alter the functional production of CD14, made an splendid candidate to influence susceptibility to asthma and atopy. Initial investigations showed remarkable variation with some studies indicating the T-allele as a risk factor, others the C-allele, and others finding no association.²¹ However, when the level of LPS (or endotoxin) exposure was considered a biologically plausible gene-past-surround interaction was revealed with data suggesting that the C-allele is a take a chance factor for allergic phenotypes at low levels of exposure, whereas the T-allele is a risk factor at loftier levels of exposure.²² Through this informative example it is clear that complex interactions between genes and surroundings make up one's mind asthma-related outcomes. Consequently, if nosotros neglect to integrate genetic and environmental factors in our study of asthma and allergy, we volition simply generate an impoverished appreciation of the etiology of atopic affliction.

While a rapidly growing number of genetic clan studies advise that TLR polymorphisms may exist associated with susceptibility to different infectious and immunologically-mediated diseases, very few of these studies have been replicated in a convincing fashion. For example, the initial association reported between MAL/TIRAP and susceptibility to tuberculosis was non replicated in some other large study.²³ As this field advances and expands to include genome-broad association studies, it is essential to appreciate that the all-time studies will include large sample sizes, statistical adjustments for multiple comparison, replication of findings with contained cohorts, multiple study designs (including case-control and family-based studies), adjustment of the analysis for population admixture, consideration of environmental variables and detailed molecular and cellular analyses to decide whether a polymorphism alters office.

2. NUCLEOTIDE OLIGOMERIZATION DOMAIN (NOD)-LIKE RECEPTORS (NLRS)

Overview of NLR Construction and Function

While TLRs are outward looking innate allowed receptors detecting microbial signatures either in the extracellular milieu or engulfed in the lumen of endocytic vesicles, nucleotide oligomerization domain (NOD)-like receptors (or NLRs) are a recently appreciated family of receptors that survey the intracellular surround.^{24 , 25} In common with other innate immune receptor systems, the NLRs take ancient origins beingness structurally reminiscent of found R-proteins that mediate plant cell defence against pathogenic bacteria. NLRs sense microbial products and metabolic stress driving inflammation through the formation of an inflammasome—a large cytoplasmic complex that activates inflammatory caspases and the production of the cytokines IL-1β and IL-18.²⁶

The human NLR family consists of at least 23 members and tin be structurally divided into four subfamily designations N-concluding effector domains.²⁷ The kickoff NLRs reported to take a direct role as intracellular pathogen detectors were NOD1 and NOD2.²⁵ Both NOD proteins detect distinct substructures generated during the synthesis, degradation and remodeling of bacterial peptidoglycan, ensuring the recognition of peptidoglycan from both Gram-positive and Gram-negative bacteria. IPAF (for ICE protease-activating factor) is another member of the NLR family known to detect bacterial pathogens.²⁸ IPAF partners with TLR5 to find infection by flagellated bacteria—TLR5 senses extracellular flagellin while IPAF focuses on intracellular flagellin. In addition to sensing microbial products, NLRs can sense metabolic stress related to infection and sterile inflammation. This sensing capacity is all-time demonstrated by NLRP3 (NLR family unit, pyrin domain-containing iii).²⁹ When triggered NLRP3 (likewise called NALP3 or cryopyrin) activates the caspase-ane 'inflammasome' leading to interleukin 1β (IL-1β) and IL-xviii processing (Figure two). The NLRP3 inflammasome appears to be activated by common metabolic 'danger signals' such as potassium efflux which occurs during inflammation due to disruption of the plasma membrane or increased extracellular ATP released by injured cells. Other clinically relevant NLRP3 activators include uric acrid, asbestos, silica and alum.

Role of NLRs in human health and disease

Although our molecular appreciation of NLRs is very recent, this form of innate immune receptors plays a key role in several human inflammatory diseases and mediates the adjuvant effect of a common vaccine component, alum.

a) NLR defects associated with inflammatory diseases

The convergence of clinically defined autoinflammatory disease with the biological science of innate amnesty and NLRs came with the discovery that three well-established autoinflammatory diseases are all caused past activating, gain-of-function mutations in NLRP3.³⁰ These diseases, collectively known every bit the cryopyrinopathies, are: (i) familial cold autoinflammatory syndrome (OMIM #120100), which presents with cold-induced fevers, urticaria-like rash, and constitutional symptoms; (ii) Muckle-Wells syndrome (OMIM #191900), which is characterized by fevers, hives, sensorineural hearing loss, and arthritis unrelated to cold exposure; and (iii) neonatal-onset multisystem inflammatory affliction (NOMID) [or chronic infantile neurologic cutaneous articular (CINCA) syndrome] (OMIM #607115), which is a devastating neonatal disease presenting with fever, urticaria and chronic hygienic meningitis. In these disorders NLRP3 mutations touch IL-1β production, and IL-1β is upregulated in these diseases.³¹ Appreciation of the role of the IL-1β axis in these diseases associated with NLRP3 mutations has allowed the rational use of targeted anti-inflammatory therapy.³² Strikingly, even the most clinically severe cryopyrinopathy, NOMID/CINCA, appears to reply well to the IL-1 receptor antagonist, anakinra.³³

More insight into the clinical relevance of NLRs arose when it was recognized that thirty–50% of patients with Crohn's disease in the Western hemisphere deport NOD2 mutations on at least one allele.^{34 , 35} The well-nigh mutual mutations are located in or near the leucine-rich repeat (LRR) domain of NOD2 and patients homozygous for the 3020insC mutation, resulting in partial truncation of the LRR, demonstrate a much more severe disease phenotype. Information technology seems paradoxical that while Crohn's disease results in overt inflammation that probably is triggered by normal bacterial flora, the NOD2 mutations associated with Crohn's disease result in a protein product less capable of responding to the bacterial ligand, muramyl dipeptide (MDP) which is a component of peptidoglycan. A unifying epitome addressing this paradox is that NOD2 appears to provide homeostatic signals to maintain the gut environment in a land that is tolerant of its flora and cells with NOD2 mutations are deficient in their production of IL-ten, an immunomodulatory and tolerogenic cytokine.³⁶ Other evidence suggests that NOD2 variants are associated with Crohn'due south affliction because they lead to a decrease in the negative regulation of TLR responses occurring in the normal gut, and thus a pathologic increase in responses to the normal flora.³⁷ Nevertheless, the genetic polymorphisms that prove a well-established association with Crohn'due south disease (including NOD2) account for only approximately twenty% of the genetic variance observed in Crohn's illness, suggesting that meaning additional genetic contributions have nevertheless to be discovered.

b) NLR contribution to vaccine responsiveness

Increased understanding of NLRs has allowed usa to shed light on the mechanism of action of vaccine adjuvants.^vi Aluminum-containing adjuvants (alum) have historically served as immunopotentiators in vaccines and keep to be the most widely used clinical adjuvants. Despite the fact that most people reading this review have received vaccines containing alum, it is just very recently that we have begun to fully appreciate the molecular mechanism of alum adjuvancy. Studies published in 2008 demonstrated that the NLRP3 (NALP3) inflammasome is involved in mediating the adjuvant effects of alum.^{38 – 40} This adjuvancy may occur direct via the triggering of the NALP3 inflammasome by alum crystals, or indirectly through release of the endogenous danger bespeak, uric acid, which afterwards activates NLRP3.

THERAPEUTIC MODULATION OF INNATE IMMUNITY

With increased appreciation of the contribution of innate immunity to human wellness and affliction, attention apace shifted to the possibility of therapeutic modulation of innate immunity. This is an surface area of active investigation, so rather than attempting to survey the field broadly, nosotros volition focus our review on recent attempts to harness the TLR system to modulate infectious and allergic diseases.

one. ACTIVATION OF TLRS AND MODULATION OF ALLERGIC IMMUNE RESPONSE

The interaction of two fields of research in the 1990s--epidemiologic investigations of the "hygiene hypothesis" in allergy and asthma, and bones inquiry in the field of TLRs--provided the impetus to investigate whether activating TLRs might correspond a novel therapeutic choice for the handling and prevention of allergy and asthma.⁴¹ TLR based therapies in allergy target in particular the dendritic cell interaction with T cells, which is a disquisitional component in shaping the Th2 immune response associated with allergic inflammation. Equally TLRs are highly expressed on dendritic cells just not on T cells, the goal of TLR based therapies in allergy and asthma is to activate dendritic cells to produce a cytokine milieu (IL-12, IFNs, etc) that favors inhibition of Th2 immune response. Thus, TLR based therapies target the innate immune response to consequently inhibit the adaptive Th2 allowed response and do not directly target T cells.

Studies have examined whether activation of TLRs tin attune allergic immune responses in pre-clinical animal models of allergy and asthma equally well as in more limited studies in human subjects. The bulk of studies have evaluated TLR9 agonists, but additional studies have also examined TLR4 agonists and a TLR7/8 agonist. Studies of the TLR9 agonist CpG Dna have demonstrated that it inhibits eosinophilic airway inflammation, Th2 cytokine responses, fungus expression, airway remodeling, and airway responsiveness in a mouse model.^{41 , 42} Administration of an inhaled TLR9 agonist for approximately 8 months to monkeys allergic to dust mite demonstrated that they had reduced eosinophilic airway inflammation, mucus, airway remodeling, and reduced airway responsiveness.⁴³ The only published studies in homo asthmatics were performed in balmy asymptomatic asthmatics treated with an inhaled TLR9 agonist prior to allergen claiming.⁴⁴ Although treatment with the inhaled TLR9 agonist increased expression of IFN-inducible genes, there was no inhibition of the early on or late phase decrease in forced expiratory book in 1 second (FEV1), nor a reduction in sputum eosinophils. These studies propose that either TLR9 based therapies volition not be effective in human subjects with asthma, or that unlike doses, routes of assistants (i.e. systemic vs local), or different study populations (symptomatic asthmatics equally opposed to allergen challenged asymptomatic asthmatics) need to be evaluated.

In add-on to TLR9 agonists, studies predominantly in mouse models have too evaluated the ability of TLR4 and TLR7/eight based therapies to modulate allergic responses. In mouse models of asthma TLR4 ligands either inhibit or potentiate allergic responses depending upon the timing of administration of the TLR4 ligand and associated allergen sensitization or challenge. In man studies in ragweed allergic rhinitis subjects, administration of a topical intranasal TLR4 ligand was rubber but did not inhibit allergic responses in asymptomatic subjects challenged intranasally with ragweed allergen.⁴⁵ Studies take likewise investigated whether assistants of a TLR7/8 agonist imiquimod would inhibit asthma responses in pre-clinical models. Imiquimod is an FDA-approved therapy which is used as a topical handling for genital warts, actinic keratoses, and superficial basal cell cancer. In pre-clinical mouse models the TLR7/8 agonist inhibits asthma responses. At present no human studies in allergy or asthma take been reported with the TLR 7/viii agonist.

2. TLR-BASED VACCINE ADJUVANTS IN ALLERGIC Disease

Studies have also examined whether administering a TLR9 agonist conjugated to an allergen would enhance the immunogenicity of the allergen when used every bit a TLR9 conjugated allergen vaccine in allergic rhinitis or asthma. Studies in mouse models have demonstrated that a conjugate of a TLR9 agonist and an allergen had a 100-fold enhanced uptake by antigen presenting cells compared to TLR9 ligand alone.^{41 , 46} The ability of a TLR9 ligand to induce a Th1 immune response is likewise approximately 100 fold greater than that induced past equivalent amounts of a non-conjugated mixture of the TLR9 ligand and allergen. In mouse models, the TLR9 allergen conjugate significantly reduces rhinitis and asthma responses.⁴¹

Thus, based on this enhanced immunogenicity of the TLR9 allergen cohabit, studies have examined whether a TLR9 ragweed allergen conjugate would reduce allergic responses in man subjects with allergic rhinitis. Studies in humans have demonstrated mixed results in terms of the effectiveness of the TLR9 ragweed allergen vaccine. Studies in ragweed allergic rhinitis subjects in Canada demonstrated that assistants of the TLR9 ragweed allergen vaccine reduced nasal mucosal biopsy eosinophil counts and Th2 cytokines, but did non reduce nasal symptom scores during the ragweed season.⁴⁷ A 2d study in Baltimore demonstrated that administration of the same TLR9 ragweed allergen vaccine significantly reduced rhinitis symptom scores in subjects with ragweed induced allergic rhinitis during the ragweed flavour.⁴⁸ Subjects treated with the TLR9 ragweed allergy vaccine also used fewer doses of allergy rescue medications during the ragweed season compared to placebo treated subjects. Interestingly, although the written report subjects immunized with the TLR9 ragweed vaccine only received six injections of the vaccine prior to the first ragweed season, the beneficial reduction in symptoms persisted through the second ragweed flavor without administration of additional vaccine.

At present in that location are limited numbers of published human studies with either assistants of TLRs alone or with TLRs conjugated to allergens. Further studies are thus needed to decide whether the interesting observations regarding TLRs in pre-clinical models will, or will non, translate into safe and effective therapeutic advances in allergy and asthma. Potential safety concerns of TLR based therapies in allergy and asthma include the consecration of autoimmune disease. However, induction of autoimmune affliction has not been observed in the limited number of clinical trials with TLR-9 based therapies.

3. TLR-BASED VACCINE ADJUVANTS IN Communicable diseases

Vaccination has proved extremely effective in preventing infectious diseases, but knowledge of the immunological mechanisms that allow vaccines to be so successful is rather limited. In dissimilarity to alive vaccines, subunit vaccines which consist of specific components of pathogens take little inherent immunogenicity and need to exist supplemented with adjuvants to promote a protective immune response. However, at that place is a paucity of licensed adjuvants for clinical use and, thus, there is a disquisitional need to develop safe and effective adjuvants. The renaissance in innate immune biological science is facilitating the rational design of novel vaccine adjuvants.⁴⁹ Characterization of the NLR system has shed light on the mechanism of action of alum adjuvancy, while our understanding of TLR function is accelerating the discovery of rubber and effective vaccine adjuvants.

An illustrative example is development of the novel adjuvant, monophosphoryl lipid A (MPL).⁵⁰ The TLR4 ligand LPS is a potent adjuvant, but its toxicity prevents use in humans. Nonetheless, MPL comes from the cell wall LPS of Gram-negative Salmonella minnesota R595 and is detoxified by balmy hydrolytic treatment and purification. MPL lacks the toxicity of LPS but retains the benign adjuvant backdrop. MPL combined with aluminum salt (referred to as the AS04 adjuvant organization) shows efficacy in a vaccine against human being papilloma virus⁵¹, and as a hepatitis B vaccine for patients with advanced renal disease.⁵² Interestingly, this adjuvant combination probable benefits from the immune enhancing capacity of both the TLR pathway (triggered past MPL) and the NALP3 inflammasome (triggered by alum crystals). Further advances in this area are nearly certain equally many other TLR ligands are existence developed as potential vaccine adjuvants.

CONCLUSIONS

In the last decade we have witnessed exhilarating advances in our understanding of the molecular mechanisms used by the innate immune organization to sense infection and trigger a protective immune response. For clinicians and scientists akin, the challenge is to now interpret this basic mechanistic understanding into a more complete appreciation of the role of innate amnesty in health and illness.

ACKNOWLEDGMENTS

We wish to admit members of the UBC Center for Understanding and Preventing Infections in Children for effective input and Rachel Victor for creating our high quality figures. Ready is supported by a Chaim Roifman Scholar Honour from the Canadian Immunodeficiency Society and a Career Development Honour from the Canadian Child Wellness Clinician Scientist Program (CCHCSP)-a CIHR Strategic Training Program, and operating grants from the Canadian Cystic Fibrosis Foundation and the CIHR Team in Mutagenesis and Infectious Diseases.

ABBREVIATIONS

CINCA	Chronic infantile neurological, cutaneous, and articular syndrome
Clammy	Damage-associated molecular pattern
HMGB-1	High mobility grouping box i
HSP	Heat-shock protein
IPAF	ICE protease-activating factor
IRAK4	Interleukin-1 receptor associated kinase four
KIR	Killer-cell immunoglobulin-similar receptors
LBP	LPS binding protein
LPS	Lipopolysaccharide
LRR	Leucine-rich echo
MAL	MyD88 adapter-like
MBL	Mannose-binding lectin
MDP	Muramyl dipeptide
MPL	Monophosphoryl lipid A
MyD88	Myeloid differentiation primary response gene 88
NLR	nucleotide oligomerization domain (NOD)-like receptors
NOMID	Neonatal-onset multisystem inflammatory affliction
PAMP	Pathogen-associated molecular blueprint
PRR	Pattern recognition receptor
RAGE	Receptor of accelerate glycation end product
SNP	Single nucleotide polymorphism
TIR	Toll/interleukin-1 receptor-like domain
TIRAP	Cost-interleukin 1 receptor (TIR) domain-containing adaptor protein
TLR	Cost-similar receptor

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accustomed for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its terminal citable form. Delight notation that during the production procedure errors may be discovered which could bear on the content, and all legal disclaimers that apply to the periodical pertain.

REFERENCES

1. Janeway CA, Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197–216. [PubMed] [Google Scholar]

2. Pancer Z, Cooper Doc. The evolution of adaptive amnesty. Annu Rev Immunol. 2006;24:497–518. [PubMed] [Google Scholar]

3. Dempsey Pw, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science. 1996;271:348–350. [PubMed] [Google Scholar]

4. Kabelitz D. Expression and function of Price-like receptors in T lymphocytes. Curr Opin Immunol. 2007;nineteen:39–45. [PubMed] [Google Scholar]

5. Beutler B. Innate immunity: an overview. Mol Immunol. 2004;40:845–859. [PubMed] [Google Scholar]

six. Janeway CA., Jr Budgeted the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol. 1989;54(Pt ane):one–xiii. [PubMed] [Google Scholar]

7. Bianchi ME. DAMPs, PAMPs and alarmins: all nosotros need to know about danger. J Leukoc Biol. 2007;81:ane–5. [PubMed] [Google Scholar]

8. Joncker NT, Raulet DH. Regulation of NK prison cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells. Immunol Rev. 2008;224:85–97. [PMC free article] [PubMed] [Google Scholar]

9. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the strong antifungal response in Drosophila adults. Prison cell. 1996;86:973–983. [PubMed] [Google Scholar]

x. Takeda 1000, Kaisho T, Akira South. Toll-like receptors. Annu Rev Immunol. 2003;21:335–376. [PubMed] [Google Scholar]

11. Akira South, Takeda Thousand. Price-like receptor signalling. Nat Rev Immunol. 2004;iv:499–511. [PubMed] [Google Scholar]

12. Ho J, Li Y, Hirschfeld AF, Mansouri D, Turvey SE. Advances in Innate Immunity: The Role of Toll-Like Receptor Signaling in Human Disease. Journal of Respiratory Affliction, Thoracic Surgery, Intensive Care, and Tuberculosis. 2004;iii:vii–14. [Google Scholar]

13. Turvey SE, Hawn TR. Towards subtlety: agreement the role of Toll-like receptor signaling in susceptibility to human being infections. Clin Immunol. 2006;120:i–9. [PubMed] [Google Scholar]

14. Picard C, Puel A, Bonnet G, Ku CL, Bustamante J, Yang K, et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science. 2003;299:2076–2079. [PubMed] [Google Scholar]

15. von Bernuth H, Picard C, Jin Z, Pankla R, Xiao H, Ku CL, et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Scientific discipline. 2008;321:691–696. [PMC gratis article] [PubMed] [Google Scholar]

xvi. Yang Chiliad, Puel A, Zhang S, Eidenschenk C, Ku CL, Casrouge A, et al. Human TLR-7-, -eight-, and -9-Mediated Induction of IFN-alpha/beta and -lambda Is IRAK-iv Dependent and Redundant for Protective Amnesty to Viruses. Immunity. 2005;23:465–478. [PMC gratis article] [PubMed] [Google Scholar]

17. Notarangelo 50, Casanova JL, Fischer A, Puck J, Rosen F, Seger R, et al. Primary immunodeficiency diseases: an update. J Allergy Clin Immunol. 2004;114:677–687. [PubMed] [Google Scholar]

xviii. Goldstein DB, Cavalleri GL. Genomics: agreement human diversity. Nature. 2005;437:1241–1242. [PubMed] [Google Scholar]

nineteen. Hawn TR, Verbon A, Lettinga KD, Zhao LP, Li SS, Laws RJ, et al. A mutual ascendant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. J Exp Med. 2003;198:1563–1572. [PMC complimentary article] [PubMed] [Google Scholar]

20. Khor CC, Chapman SJ, Vannberg FO, Dunne A, Murphy C, Ling EY, et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet. 2007;39:523–528. [PMC gratis commodity] [PubMed] [Google Scholar]

21. Martinez FD. CD14, endotoxin, and asthma chance: actions and interactions. Proc Am Thorac Soc. 2007;four:221–225. [PMC free commodity] [PubMed] [Google Scholar]

22. Simpson A, John SL, Jury F, Niven R, Woodcock A, Ollier WE, et al. Endotoxin exposure, CD14, and allergic affliction: an interaction between genes and the surroundings. Am J Respir Crit Care Med. 2006;174:386–392. [PubMed] [Google Scholar]

23. Nejentsev South, Thye T, Szeszko JS, Stevens H, Balabanova Y, Chinbuah AM, et al. Assay of association of the TIRAP (MAL) S180L variant and tuberculosis in three populations. Nat Genet. 2008;40:261–262. author respond 2–3. [PubMed] [Google Scholar]

24. Chen M, Shaw MH, Kim Y-G, Nuñez G. NOD-Similar Receptors: Role in Innate Immunity and Inflammatory Illness. Annual Review of Pathology: Mechanisms of Disease. 2009;iv:365–398. [PubMed] [Google Scholar]

25. Benko S, Philpott DJ, Girardin SE. The microbial and danger signals that activate Nod-like receptors. Cytokine. 2008;43:368–373. [PubMed] [Google Scholar]

26. Martinon F, Mayor A, Tschopp The Inflammasomes: Guardians of the Body. Annual Review of Immunology. 2009;27:229–265. [PubMed] [Google Scholar]

27. Ting JPY, Lovering RC, Alnemri ES, Bertin J, Boss JM, Davis BK, et al. The NLR Factor Family: A Standard Nomenclature. Immunity. 2008;28:285–287. [PMC gratis commodity] [PubMed] [Google Scholar]

28. Miao EA, Andersen-Nissen Due east, Warren SE, Aderem A. TLR5 and Ipaf: dual sensors of bacterial flagellin in the innate immune system. Semin Immunopathol. 2007;29:275–288. [PubMed] [Google Scholar]

29. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol. 2009;x:241–247. [PMC free commodity] [PubMed] [Google Scholar]

30. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*) Annu Rev Immunol. 2009;27:621–668. [PMC gratis article] [PubMed] [Google Scholar]

31. Aksentijevich I, Nowak Thou, Mallah M, Chae JJ, Watford WT, Hofmann SR, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 2002;46:3340–3348. [PMC free commodity] [PubMed] [Google Scholar]

32. Hoffman HM, Rosengren S, Boyle DL, Cho JY, Nayar J, Mueller JL, et al. Prevention of cold-associated astute inflammation in familial cold autoinflammatory syndrome by interleukin-one receptor antagonist. Lancet. 2004;364:1779–1785. [PMC free article] [PubMed] [Google Scholar]

33. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med. 2006;355:581–592. [PMC free article] [PubMed] [Google Scholar]

34. Hugot JP, Chamaillard K, Zouali H, Lesage Due south, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn'due south disease. Nature. 2001;411:599–603. [PubMed] [Google Scholar]

35. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn'southward disease. Nature. 2001;411:603–606. [PubMed] [Google Scholar]

36. Noguchi E, Homma Y, Kang X, Netea MG, Ma X. A Crohn's illness-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat Immunol. 2009;10:471–479. [PMC free commodity] [PubMed] [Google Scholar]

37. Strober Due west, Kitani A, Fuss I, Asano North, Watanabe T. The molecular basis of NOD2 susceptibility mutations in Crohn's illness. Mucosal Immunol. 2008;1 Suppl ane:S5–S9. [PMC complimentary article] [PubMed] [Google Scholar]

38. Franchi 50, Nunez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol. 2008;38:2085–2089. [PMC free article] [PubMed] [Google Scholar]

39. Li H, Willingham SB, Ting JP, Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant event are mediated by NLRP3. J Immunol. 2008;181:17–21. [PMC free article] [PubMed] [Google Scholar]

40. Eisenbarth SC, Colegio OR, O'Connor Due west, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008;453:1122–1126. [PMC complimentary commodity] [PubMed] [Google Scholar]

41. Horner AA, Redecke V, Raz East. Toll-similar receptor ligands: hygiene, atopy and therapeutic implications. Curr Opin Allergy Clin Immunol. 2004;4:555–561. [PubMed] [Google Scholar]

42. Broide D, Schwarze J, Tighe H, Gifford T, Nguyen Medico, Malek S, et al. Immunostimulatory Deoxyribonucleic acid sequences inhibit IL-v, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol. 1998;161:7054–7062. [PubMed] [Google Scholar]

43. Fanucchi MV, Schelegle ES, Baker GL, Evans MJ, McDonald RJ, Gershwin LJ, et al. Immunostimulatory oligonucleotides benumb airways remodeling in allergic monkeys. Am J Respir Crit Care Med. 2004;170:1153–1157. [PMC gratis article] [PubMed] [Google Scholar]

44. Gauvreau GM, Hessel EM, Boulet LP, Coffman RL, O'Byrne PM. Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses. Am J Respir Crit Care Med. 2006;174:fifteen–20. [PubMed] [Google Scholar]

45. Casale TB, Kessler J, Romero FA. Prophylactic of the intranasal toll-like receptor 4 agonist CRX-675 in allergic rhinitis. Ann Allergy Asthma Immunol. 2006;97:454–456. [PubMed] [Google Scholar]

46. Shirota H, Sano Thou, Hirasawa N, Terui T, Ohuchi K, Hattori T, et al. Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen past dendritic cells. J Immunol. 2001;167:66–74. [PubMed] [Google Scholar]

47. Tulic MK, Fiset PO, Christodoulopoulos P, Vaillancourt P, Desrosiers M, Lavigne F, et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol. 2004;113:235–241. [PubMed] [Google Scholar]

48. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. Northward Engl J Med. 2006;355:1445–1455. [PubMed] [Google Scholar]

49. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Jail cell. 2006;124:849–863. [PubMed] [Google Scholar]

50. Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A every bit a safe and effective vaccine adjuvant. Jail cell Mol Life Sci. 2008;65:3231–3240. [PMC complimentary article] [PubMed] [Google Scholar]

51. Schwarz TF. AS04-adjuvanted human being papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Skillful Rev Vaccines. 2008;7:1465–1473. [PubMed] [Google Scholar]

52. Kong NCT, Beran J, Kee SA, Miguel JL, Sanchez C, Bayas JM, et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int. 2007;73:856–862. [PubMed] [Google Scholar]

pollarddishemeard.blogspot.com

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2832725/

Share this post